Literature DB >> 35778609

Studies on Streptomyces sp. SN-593: reveromycin biosynthesis, β-carboline biomediator activating LuxR family regulator, and construction of terpenoid biosynthetic platform.

Shunji Takahashi1.   

Abstract

Streptomyces represents an important reservoir for biologically active natural products. Understanding the biosynthetic mechanism and the mode of gene expression is important for enhanced metabolite production and evaluation of biological activities. This review provides an overview of biosynthetic studies investigating reveromycin and β-carboline biomediators that enhanced the production of reveromycin in Streptomyces sp. SN-593 through activation of the LuxR family regulator. Furthermore, based on the optimal expression of a pathway specific regulator controlling the mevalonate pathway gene cluster, Streptomyces sp. SN-593 was developed as a platform for terpenoid compounds mass production.
© 2022. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35778609     DOI: 10.1038/s41429-022-00539-1

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   3.424


  60 in total

Review 1.  Lessons from natural molecules.

Authors:  Jon Clardy; Christopher Walsh
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

Review 2.  Combinatorial biosynthesis of reduced polyketides.

Authors:  Kira J Weissman; Peter F Leadlay
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

Review 3.  Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms.

Authors:  Michael A Fischbach; Christopher T Walsh
Journal:  Chem Rev       Date:  2006-08       Impact factor: 60.622

4.  Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.

Authors:  Hiroaki Muguruma; Seiji Yano; Soji Kakiuchi; Hisanori Uehara; Makoto Kawatani; Hiroyuki Osada; Saburo Sone
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

Review 5.  Genomic basis for natural product biosynthetic diversity in the actinomycetes.

Authors:  Markus Nett; Haruo Ikeda; Bradley S Moore
Journal:  Nat Prod Rep       Date:  2009-09-01       Impact factor: 13.423

6.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2020-03-12       Impact factor: 4.050

7.  Reveromycin A biosynthesis uses RevG and RevJ for stereospecific spiroacetal formation.

Authors:  Shunji Takahashi; Atsushi Toyoda; Yasuyo Sekiyama; Hiroshi Takagi; Toshihiko Nogawa; Masakazu Uramoto; Ryuichiro Suzuki; Hiroyuki Koshino; Takuto Kumano; Suresh Panthee; Tohru Dairi; Jun Ishikawa; Haruo Ikeda; Yoshiyuki Sakaki; Hiroyuki Osada
Journal:  Nat Chem Biol       Date:  2011-06-05       Impact factor: 15.040

8.  Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.

Authors:  Je-Tae Woo; Makoto Kawatani; Masanori Kato; Toshimasa Shinki; Takayuki Yonezawa; Naoki Kanoh; Hiroshi Nakagawa; Masamichi Takami; Kun Hyung Lee; Paula H Stern; Kazuo Nagai; Hiroyuki Osada
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

9.  Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone.

Authors:  Akihiro Yano; Shinji Tsutsumi; Shiro Soga; Min-Jung Lee; Jane Trepel; Hiroyuki Osada; Len Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-07       Impact factor: 11.205

10.  β-carboline chemical signals induce reveromycin production through a LuxR family regulator in Streptomyces sp. SN-593.

Authors:  Suresh Panthee; Naoko Kito; Teruo Hayashi; Takeshi Shimizu; Jun Ishikawa; Hiroshi Hamamoto; Hiroyuki Osada; Shunji Takahashi
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.